IL1A and COVID-19: Anakinra is an antagonist of IL‐1 receptor, which inhibits IL‐1α and IL‐1β activities, and is approved by the FDA to be used to treat adult COVID-19 inpatients with positiveness of COVID-19 with pneumonia and requiring supplemental oxygen.